The quantification of infarct size

Research output: Contribution to journalArticle

278 Citations (Scopus)

Abstract

We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.

Original languageEnglish (US)
Pages (from-to)1533-1542
Number of pages10
JournalJournal of the American College of Cardiology
Volume44
Issue number8
DOIs
StatePublished - Oct 19 2004

Fingerprint

Single-Photon Emission-Computed Tomography
Multicenter Studies
Biomarkers
Myocardial Infarction
Magnetic Resonance Imaging
Technetium Tc 99m Sestamibi
Myocardial Perfusion Imaging
Troponin
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

The quantification of infarct size. / Gibbons, Raymond J; Valeti, Uma S.; Araoz, Philip A; Jaffe, Allan S.

In: Journal of the American College of Cardiology, Vol. 44, No. 8, 19.10.2004, p. 1533-1542.

Research output: Contribution to journalArticle

@article{04f41d688dee4fb9a9f0c32d7004f293,
title = "The quantification of infarct size",
abstract = "We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.",
author = "Gibbons, {Raymond J} and Valeti, {Uma S.} and Araoz, {Philip A} and Jaffe, {Allan S}",
year = "2004",
month = "10",
day = "19",
doi = "10.1016/j.jacc.2004.06.071",
language = "English (US)",
volume = "44",
pages = "1533--1542",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - The quantification of infarct size

AU - Gibbons, Raymond J

AU - Valeti, Uma S.

AU - Araoz, Philip A

AU - Jaffe, Allan S

PY - 2004/10/19

Y1 - 2004/10/19

N2 - We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.

AB - We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=5744249741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5744249741&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.06.071

DO - 10.1016/j.jacc.2004.06.071

M3 - Article

C2 - 15489082

AN - SCOPUS:5744249741

VL - 44

SP - 1533

EP - 1542

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 8

ER -